Ironwood Pharmaceuticals Inc
NASDAQ:IRWD

Watchlist Manager
Ironwood Pharmaceuticals Inc Logo
Ironwood Pharmaceuticals Inc
NASDAQ:IRWD
Watchlist
Price: 4.08 USD -5.12% Market Closed
Market Cap: 663.7m USD

During the last 3 months Ironwood Pharmaceuticals Inc insiders have not bought any shares, and sold 20k USD worth of shares. The stock price has increased by 158% over this period (open performance analysis).

The last transaction was made on Nov 17, 2025 by Gaskins Tammi L , who sold 20k USD worth of IRWD shares.

Last Transactions:
Gaskins Tammi L
$-20k
Gaskins Tammi L
$-1.1k
John Minardo
$-6.5k
Silver Ronald
$-2.4k
Martini Gregory S.
$-1.1k
Gaskins Tammi L
$-1.5k
Mccourt Thomas A
$-7.7k
Martini Gregory S.
$-21.2k
Mccourt Thomas A
$-244.8k
Silver Ronald
$-21.2k
Shetzline Michael
$-72.6k
John Minardo
$-68.5k
Davis Andrew
$-21.9k
Emany Sravan Kumar
$-44.9k
John Minardo
$-42.3k
Silver Ronald
$-13.3k
Mchugh Julie
$-143.2k
Moukheibir Catherine
$-235.1k
Moukheibir Catherine
$-282.5k
Mccourt Thomas A
$-436.1k
Shetzline Michael
$-104k
John Minardo
$-112.3k
Davis Andrew
$-146.6k
Duane Jon R
$+60.2k
Emany Sravan Kumar
$+100.2k
John Minardo
$-722.1k
Shetzline Michael
$-588.5k
Silver Ronald
$-120.5k
Davis Andrew
$-150.1k
Mccourt Thomas A
$-2.7m
Kessler Marla L
$-111.1k
Davis Andrew
$-31.9k
View All Transactions

During the last 3 months Ironwood Pharmaceuticals Inc insiders have not bought any shares, and sold 20k USD worth of shares. The stock price has increased by 158% over this period (open performance analysis).

The last transaction was made on Nov 17, 2025 by Gaskins Tammi L , who sold 20k USD worth of IRWD shares.

Sold
0-3
months
20k USD
1
3-6
months
11.1k USD
4
6-9
months
9.2k USD
2
9-12
months
428.3k USD
5
Bought
0-3
months
0
0 USD
3-6
months
0
0 USD
6-9
months
0
0 USD
9-12
months
0
0 USD

Ironwood Pharmaceuticals Inc
Insider Trading Chart

Ironwood Pharmaceuticals Inc
Insiders Performance

1 Week Later 1 Month Later 3 Months Later 6 Months Later 1 Year Later
Average Return
Median Return
Win Rate

Ironwood Pharmaceuticals Inc
Last Insider Transactions

Global
Insiders Monitor

Ironwood Pharmaceuticals Inc
Glance View

Ironwood Pharmaceuticals, Inc. is a healthcare company, which focuses on the development and commercialization of Gastrointestinal (GI) product opportunities in areas of significant unmet need, leveraging demonstrated expertise and capabilities in GI diseases. The company is headquartered in Boston, Massachusetts and currently employs 219 full-time employees. The company went IPO on 2010-02-03. The company operates in the human therapeutics business segment. Its product candidate LINZESS (linaclotide) is available to adult men and women suffering from IBS-C or CIC in the United States, and Mexico and to adult men and women suffering from IBS-C. Its linaclotide is available under the trademarked name CONSTELLA to adult men and women suffering from IBS-C or CIC in Canada, and to adult men and women suffering from IBS-C in certain European countries. The Company’s products pipeline includes IW-3300, which is a GC-C agonist, for the potential treatment of visceral pain conditions, including interstitial cystitis/bladder pain syndrome and endometriosis, and CNP-104 is a tolerizing immune modifying nanoparticle.

IRWD Intrinsic Value
7.89 USD
Undervaluation 48%
Intrinsic Value
Price

What is Insider Trading?

Insider trading refers to the buying or selling of a company’s stock by individuals with access to non-public, material information about the company.

While legal insider trading occurs when insiders follow disclosure rules, illegal insider trading involves trading based on confidential information and is prohibited by law.

Why is Insider Trading Important?

It isn't a coincidence that corporate executives seem to always buy at the right times. After all, they have access to every bit of company information you could ever want.

However, the fact that company executives have unique insights doesn't mean that individual investors are always left in the dark. Insider trading data is out there for all who want to use it.

Peter Lynch

Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise.

Back to Top